LQAI yields 1.11% · PFE yields 6.13%● Live data
📍 PFE pulled ahead of the other in Year 9
Combined, LQAI + PFE cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of LQAI + PFE for your $10,000?
LQAI launches through a partnership between the AI research division of LG, the South Korean company that makes TVs and home appliances, and Qraft Tech. The fund employs a proprietary artificial intelligence (AI) system for selection while maintaining oversight from the fund's adviser. The AI identifies patterns and creates a balanced exposure to the five factors influencing the US market: quality (profitability), size (market capitalization), value (price-to-book ratio), momentum, and volatility. The fund evaluates the impact of each factor on companies and selects the top 100 stocks based on the average distribution of each stock's relative superiority in price appreciation. These stocks are also poised to outperform their peers in the upcoming month. Due to the monthly updates to the database, LQAI is expected to trade securities frequently, potentially resulting in a high portfolio turnover. The Fund restricts single company weightings to 10% and securities with over 5% weighting to 40% of assets in aggregate. Although investments are heavily reliant on QRAFT AI recommendations, the adviser maintains the final decision-making authority in investment choices.
Full LQAI Calculator →Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Full PFE Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.